Myeloid derived suppressor cells (MDSC) contribute significantly to the malignant characters conferred by hypoxic tumor microenvironments. However, selective biomarkers of MDSC function in this critical setting have not been defined. Here we report that miR-210 expression is elevated by HIF-1α in MDSC localized to tumors, compared to splenic MDSC from tumor-bearing mice. In tumor MDSC, we determined that HIF-1α was bound directly to a transcriptionally active hypoxia-response element in the miR-210 proximal promoter. miR-210 overexpression was sufficient to enhance MDSC-mediated T cell suppression under normoxic conditions, while targeting hypoxia-induced miR-210 was sufficient to decrease MDSC function against T cells. Mechanistic investigations revealed that miR-210 modulated MDSC function by increasing arginase activity and NO production, without affecting ROS, IL-6 or IL-10 production or expression of PD-L1. In splenic MDSC, miR-210 regulated Arg1, Cxcl12 and IL-16 at the levels of both mRNA and protein, the reversal of which under normoxic conditions decreased T cell suppressive effects and IFN-gamma production. Interestingly, miR-210 overexpression or targeting IL-16 or CXCL12 enhanced the immune suppressive activity of MDSC in vivo resulting in increased tumor growth. Taken together, these results provide a preclinical rationale to explore miR-210 inhibitory oligonucleotides as adjuvants to boost immunotherapeutic responses in cancer patients.


